Literature DB >> 24764786

Commentary: sofosbuvir for treatment of hepatitis C virus genotype 2 or 3 infection in patients without treatment options.

Steven L Flamm1.   

Abstract

Entities:  

Year:  2013        PMID: 24764786      PMCID: PMC3992066     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN: 1554-7914


× No keyword cloud information.
  7 in total

Review 1.  Adverse effects of drugs in the treatment of viral hepatitis.

Authors:  Francesco Negro
Journal:  Best Pract Res Clin Gastroenterol       Date:  2010-04       Impact factor: 3.043

Review 2.  Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C.

Authors:  Mark S Sulkowski; Curtis Cooper; Bela Hunyady; Jidong Jia; Pavel Ogurtsov; Markus Peck-Radosavljevic; Mitchell L Shiffman; Cihan Yurdaydin; Olav Dalgard
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-03-08       Impact factor: 46.802

3.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Authors:  Michael W Fried; Mitchell L Shiffman; K Rajender Reddy; Coleman Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampiero Carosi; Daniel Dhumeaux; Antonio Craxi; Amy Lin; Joseph Hoffman; Jian Yu
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

4.  Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

Authors:  Mitchell L Shiffman; Fredy Suter; Bruce R Bacon; David Nelson; Hugh Harley; Ricard Solá; Stephen D Shafran; Karl Barange; Amy Lin; Ash Soman; Stefan Zeuzem
Journal:  N Engl J Med       Date:  2007-07-12       Impact factor: 91.245

5.  Diagnosis, management, and treatment of hepatitis C: an update.

Authors:  Marc G Ghany; Doris B Strader; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

6.  PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.

Authors:  Angela M Lam; Eisuke Murakami; Christine Espiritu; Holly M Micolochick Steuer; Congrong Niu; Meg Keilman; Haiying Bao; Veronique Zennou; Nigel Bourne; Justin G Julander; John D Morrey; Donald F Smee; David N Frick; Julie A Heck; Peiyuan Wang; Dhanapalan Nagarathnam; Bruce S Ross; Michael J Sofia; Michael J Otto; Phillip A Furman
Journal:  Antimicrob Agents Chemother       Date:  2010-06-01       Impact factor: 5.191

7.  Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.

Authors:  Edward J Gane; Catherine A Stedman; Robert H Hyland; Xiao Ding; Evguenia Svarovskaia; William T Symonds; Robert G Hindes; M Michelle Berrey
Journal:  N Engl J Med       Date:  2013-01-03       Impact factor: 91.245

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.